Penumbra Inc. logo

Penumbra Inc. (PEN)

Market Closed
3 Jun, 20:00
NYSE NYSE
$
319. 37
+0.63
+0.1977%
$
12.54B Market Cap
231.58 P/E Ratio
- Div Yield
364,078 Volume
2.03 Eps
$ 318.74
Previous Close
Add Transaction
Day Range
318.35 319.7
Year Range
221.26 362.41
Want to track PEN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say

Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 year ago
Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again

Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again

Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 year ago
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?

Penumbra (PEN) Earnings Expected to Grow: Should You Buy?

Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Reasons to Retain Penumbra Stock in Your Portfolio for Now

Reasons to Retain Penumbra Stock in Your Portfolio for Now

PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts.

Zacks | 1 year ago
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues

New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues

Penumbra expects to materially increase both revenues and profitability in the company's international business in the next few years.

Zacks | 1 year ago
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail

Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail

Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.

Zacks | 1 year ago
Penumbra (PEN) Upgraded to Buy: Here's Why

Penumbra (PEN) Upgraded to Buy: Here's Why

Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 year ago
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.

Zacks | 1 year ago
Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript

Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript

Penumbra, Inc. (NYSE:PEN ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Larry Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Bill Plovanic - Canaccord Richard Newitter - Truist Securities Samantha Kurtz - Piper Sandler Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Shagun Singh - RBC Capital Markets Michael Kratky - Leerink Partners Operator Good afternoon. My name is Rob and I will be your conference operator today.

Seekingalpha | 1 year ago
Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings

Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings

The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 year ago
Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates

Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates

Penumbra (PEN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.76 per share a year ago.

Zacks | 1 year ago
Should You Add Penumbra Stock to Your Portfolio Right Now?

Should You Add Penumbra Stock to Your Portfolio Right Now?

PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.

Zacks | 1 year ago
Loading...
Load More